SGTX(Delisted)
SigilonยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SGTX
Sigilon Therapeutics, Inc.
A biotech company that develops and commercializes therapies for the treatment of cronic diseases
100 Binney Street, Suite 600, Cambridge, MA 02142
--
Sigilon Therapeutics, Inc., was incorporated under the laws of Delaware on May 14, 2015 as Sigilon, Inc., and changed its name in July 2017. The company is a clinical-stage biotechnology company pioneering the development of novel therapies and seeking to develop functional therapies for patients with chronic diseases by delivering stable and durable levels of therapeutic molecules to patients.
Company Financials
EPS
SGTX has released its 2023 Q1 earnings. EPS was reported at -0.23, versus the expected -0.23, meeting expectations. The chart below visualizes how SGTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SGTX has released its 2023 Q2 earnings report, with revenue of 5.90M, reflecting a YoY change of 104.65%, and net profit of -7.51M, showing a YoY change of 47.68%. The Sankey diagram below clearly presents SGTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
